Acute respiratory distress syndrome (ARDS) is a life threatening condition characterized by severe hypoxemia due to pulmonary gas exchange failure and was first recognized in 1960s.Since its first description, it has undergone intensive research in the past few decades to understand its pathogenesis and therapies. Despite this, the recommended therapies to decrease mortality in ARDS remain limited and include low-tidal volume mechanical ventilation, prone ventilation and recently,the ECMO rescue therapy in extreme cases. This review article will summarize the key features of ARDS with a brief overview of the therapeutic options in the management of ARDS.
INTRODUCTION

Acute respiratory distress syndrome (ARDS)
is an acute life threatening inflammatory lung injury manifested by hypoxia and stiff lungs due to increased pulmonary vascular permeability and almost always requiring mechanical ventilation support. [1] ARDS represents an acute response to diverse provoking trigger factors and etiologies, resulting bilateral lung opacities on radiography and hypoxemia.
ARDS was first described by Ashbaugh et al. in 1967 , [2] and since then there have been multiple studies addressing the various clinical aspects of the syndrome, its pathogenesis, risk factors, and treatment. However, despite the intense research, only few effective therapies for ARDS have been postulated, including the lung protection strategies.
In this review article, authors will summarize the key features of ARDS, a brief overview of the therapeutic options in the management of ARDS.
DEFINITION
ARDS was first defined in 1994 by the American-European Consensus Conference (AECC) as the acute onset of hypoxemia (arterial partial pressure of oxygen to fraction of inspired oxygen [PaO 2 /FIO 2 ] ≤ 200 mm Hg) with bilateral infiltrates on frontal chest radiograph, with no evidence of left atrial hypertension and acute lung injury (ALI) was defined using similar criteria, but having PaO 2 /FIO 2 ≤ 300 mm Hg. [3] Over the years, with the ongoing research on this topic, issues regarding the validity and reliability of this definition emerged.
A panel of experts assembled in 2011 (an initiative of the European Society of Intensive Care Medicine endorsed by the American Thoracic Society and the Society of Critical Care Medicine) and developed the Berlin Definition of ARDS using a consensus process. [1] The Berlin definition require all four criteria's to be present for diagnosis of ARDS (1) Timing: Respiratory symptoms must have begun within one week of a known clinical insult, or the patient must have new or worsening symptoms during the past week. (2) Chest imaging: Bilateral opacities consistent with pulmonary edema must be present on a chest radiograph or computed tomographic scan, which is not fully explained by pleural effusions, lobar collapse, lung collapse, or pulmonary nodules. (3) Origin of edema: The patient's respiratory failure must not be fully explained by cardiac failure or fluid overload. An objective assessment (e.g., echocardiography) to exclude hydrostatic pulmonary edema is required if no risk factors for ARDS are present. Compared with the AECC definition, the Berlin Definition had a better prediction for mortality with increased percentage of mortality associated with increasing stages of ARDS: mild 27%, moderate 32%, and severe 45% with 95% CI.
[1]
PATHOPHYSIOLOGY AND RISK FACTORS
ARDS occurs as a consequence of an alveolar injury due to various causes producing diffuse alveolar damage. This causes the release of pro-inflammatory cytokines [tumor necrosis factor, interleukin (IL)-1, IL-6, IL-8], which recruit neutrophils to the lungs, where they get activated and release toxic mediators (reactive oxygen species and proteases) that damage the capillary endothelium and alveolar epithelium leading to alveolar edema. [4] This, eventually, leads to impairment of gas exchange, decreased lung compliance, and increased pulmonary arterial pressure.
Pathological stages: The initial stage is the exudative stage, characterized by diffuse alveolar damage. The second stage of proliferation develops after approximately 10-14 days, characterized by resolution of pulmonary edema, proliferation of type II alveolar cells, squamous metaplasia, interstitial infiltration by myofibroblasts, and early deposition of collagen. Some patients progress to the third stage of fibrosis, characterized by obliteration of normal lung architecture, diffuse fibrosis, and cyst formation. [5] CURRENT THERAPIES
Lung-protective ventilation
Various trials have demonstrated that mechanical ventilation with lower tidal volumes (LTV) and airway pressures (tidal volume of 4-6 ml/kg predicted body weight and maintenance of plateau pressure between 25 and 30 cm H 2 O) reduces mortality in ALI and ARDS. [6] This lung-protective ventilation preserves barrier properties of the alveolar endothelium and alveolar epithelium by preventing alveolar overdistension, which is one of the major causes of ventilator-induced lung injury. [6] [7] [8] [9] [10] [11] The concept of open lung ventilation uses low tidal volume with high PEEP with the rationale that LTV will minimize the damage due to overdistension while the high PEEP will minimize the cyclic atelectasis [6] , has been shown to have a beneficial effect on the outcome of the patients. Lungprotective ventilation also down regulates mechanosensitive pro-inflammatory pathways, resulting in reduced neutrophil accumulation in the alveoli and lower plasma levels of IL-6, IL-8, and TNF. [7, 12] Prone ventilation Prone ventilation showed improvement in the level of oxygenation and thus improved the outcome in patients with ARDS having severe hypoxia. [13] [14] [15] This effect is due to the reduction in the trans-pulmonary pressure gradient on making the patient prone, which helps in recruiting the collapsed areas of the lung without causing significant increase in the airway pressures. In the study by De Jong et al. (2013) , prone ventilation was found to be a significantly effective in obese patients with ARDS than in non-obese patients. [16] Extracorporeal membrane oxygenation ECMO is an advanced circulatory and ventilatory support system, which is used to salvage the patients with refractory hypoxemia when the conventional treatment fails. The technique has been used successfully as a rescue therapy for the severe ARDS cases as shown by the CESAR trial in 2009 [17] . The evidence to support the use of ECMO as a primary treatment in ARDS is lacking and needs further research. [18, 19] High-frequency oscillatory ventilation High-frequency oscillatory ventilation (HFOV) seemed ideal for lung protection in ARDS, but the OSCAR study concluded with no 30-day survival benefit or cost benefit in patients in whom HFOV was used [20] . The meta-analysis of randomized control trials (RCT) by Gu et al. (2014) also concluded that with use of HFOV, there was no improvement in survival in ARDS patients, although it had no increase the risk of barotrauma or hypotension and also reduced the risk of oxygenation failure. [21] Neuromuscular blockade Neuromuscular blocking agents (NMBAs) are commonly used in ARDS, but their use remains controversial. In recent meta-analysis and review, the use of short term NMBAs in ARDS patients have shown a beneficial outcome mainly by decreasing the barotrauma and ventilator-induced lung injury. [22, 23] Fluid-conservative therapy In ARDS patients, due to increased alveolar vascular permeability, there is presence of alveolar edema, which may get worsened as a consequence of fluid overload. The conservative approach of fluid management in ARDS has been proven to be beneficial in reducing ventilator days but doesn't improve survival. [24] Intravenous β-2 agonist in ARDS The BALTI trial (2006) was a single center RCT, which showed the benefit of intravenous infusion of Salbutamol for 7 days in patients with ARDS, by causing significant reductions in extravascular lung water and plateau airway pressures [25] . Despite this, the recent evidence from the BALTI 2 trial, which is a multicenter RCT, showed no benefit of intravenous β-2 agonist (Salbutamol) in patients with ARDS and concluded that this may have significant detrimental effects with increase in mortality. [26] Corticosteroids in ARDS ARDS, despite being an acute lung inflammatory disease with involvement of diverse inflammatory cells and mediators, the use of anti-inflammatory corticosteroids have not shown improved survival. A systematic review and meta-analysis by Ruan et al. (2014) , which included 8 RCTs and 10 cohort studies concluded that corticosteroids may be harmful in some patients and not to be routinely used in ARDS. [27] Experimental trials In experimental models of ARDS in rats, bone-marrow derived mesenchymal stem cells (MSCs) reduce the severity of ventilator-induced lung injury by enhancing the regeneration of lung tissue and its repair [28, 29] . Studies have shown that MSCs could be of benefit by their property to reduce the production of inflammatory mediators, leukocyte infiltration, tissue injury, and pulmonary failure. [30] 
CONCLUSION
There has been considerable research on ARDS in the past decade and better understanding of its pathogenesis. Despite this, the effective therapeutic measures to decrease mortality in ARDS seem to be low-tidal volume mechanical ventilation, prone ventilation for severe ARDS cases; and in life-threatening cases not responding to the conventional therapies, ECMO rescue technology serves as a bridge to recovery.
